news

  • 23 April 2018
    TopiVert to Present TOP1630 Clinical Proof-of-Concept Data in Dry Eye Syndrome at the ARVO 2018 Annual Meeting

    TopiVert Pharma Ltd (“TopiVert” or the “Company”), a clinical-stage biotechnology company developing Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, locally-acting medicines for the treatment of chronic inflammatory ocular and gastrointestinal diseases, today announces that its clinical abstract “A Phase 2 randomized, double-masked, placebo-controlled study of novel narrow spectrum kinase inhibitor TOP1630 for the treatment of dry eye syndrome” has been selected for presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting taking place 29 April–03 May 2018 in Honolulu, Hawaii.

    The details of the poster presentation are as follows:

    Session title: Dry Eye Clinical I

    Title: A Phase 2 randomized, double-masked, placebo-controlled study of novel narrow spectrum kinase inhibitor TOP1630 for the treatment of dry eye syndrome

    Authors: Mike Taylor et al.

    Abstract number: 947 – B0125

    Date/Time/Location: Sunday 29 April 2018/3:15PM–5:00PM/Exhibit Hall

    Steve Webber, TopiVert’s Chief Scientific Officer, said: “We are delighted to present, publicly for the first time at the ARVO Annual Meeting, our important clinical data which demonstrate that TOP1630 displays convincing efficacy in treating both the signs and symptoms of dry eye syndrome with placebo-like tolerability. This compelling clinical data supports our plans to advance TOP1630 into latestage development for dry eye syndrome later this year and to explore the use of NSKIs as potential treatments for other ocular inflammatory disorders.”